Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen

Bristol-Myers

Gilead Sciences

GlaxoSmithKline

Pfizer

Drugmakers including Bristol-Myers Squibb Co, Gilead Sciences Inc, and Biogen Inc hiked U.S. list prices on more than 50 drugs on Wednesday, bringing total New Year's Day drug price increases to more than 250, according to data analyzed by healthcare research firm 3 Axis Advisors.

More drugmakers hike U.S. prices as new year begins

Sanofi's Acquisition Enhances Its Immuno-Oncology Pipeline With Potential Game-Changing Product

Sanofi: Still Waiting For Champagne

Sanofi has the perfect gift for investors: Investment in its most promising businesses with plans to keep growing the dividend.

Sanofi Says Its $2.5 Billion Biotech Takeover Is Just the Beginning

AbbVie

Allergan

Celgene

Eli Lilly

Medicines

Merck

Novartis

Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

Biotech Stocks Burn A Hole In Big Pharma's Pocket. Look For More In 2020

Regeneron Pharmaceuticals

Sanofi (SNY) intends to amend its antibody collaboration with Regeneron related to Kevzara and Praulent into a royalty-based agreement. Agreement terms for Dupixent to remain intact.

Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent

Sanofi (SNY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Sanofi (SNY) Looks Good: Stock Adds 6.2% in Session

AutoZone

Virgin Galactic

A host of factors helped create some big winners on Tuesday.

Why Virgin Galactic Holdings, Sanofi, and AutoZone Jumped Today

Sanofi, with sales falling in its older businesses, boosts its higher-growth immuno-oncology business with the $2.5 billion purchase of Synthorx.

Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were rebounding Tuesday as investors digested French pharma giant and collaboration partner Sanofi SA's (NASDAQ: SNY) potential liquidation of its Regeneron stake — and the restructuring of a collaboration agreement between the two.

Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations

SNY stock broke out Tuesday after pharmaceutical company unveiled a plan to restructure its agreement with Regeneron Pharmaceuticals. Sanofi will also restructure its business.

Why This Pharmaceutical Stock Broke Out Bullishly In Early Action

Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.

Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research

Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.

Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms

ArQule

Spark Therapeutics

Roche Holding AG

Synthorx Inc

Week Begins with Biotech Mergers

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.

Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio

Synthorx, Inc. (NASDAQ: THOR) shares are trading sharply higher after the company announced it would be acquired by Sanofi (NYSE: SNY) for $68 per share in cash, which represents an aggregate equity value of $2.5 billion.

Synthorx To Be Acquired By Sanofi For $2.5B

French pharma giant Sanofi agreed to buy Synthorx Inc. for $2.5 billion, more than double the U.S.

Sanofi To Buy Synthorx For $2.5 Billion To Expand In Cancer

France's Sanofi on Monday agreed to buy California-headquartered biotechnology firm Synthorx in a cash deal worth about $2.5 billion as it steps up a push in the lucrative field of cancer drugs under its new chief executive.

France's Sanofi to buy biotech firm Synthorx for $2.5 billion

France's Sanofi  said on Monday it had agreed to buy Synthorx in a cash deal worth around $2.5 billion as it seeks to beef up its immuno-oncology pipeline.

France's Sanofi to buy Synthorx for $2.5 billion

With new promising results for its diabetes drug, is Sanofi a good investment right now?

Is Sanofi's Stock a Buy?

Amgen

Swiss drugmaker Novartis  is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co  as it challenges cardiovascular medicines from Amgen Inc , Sanofi  and Regeneron Pharmaceuticals.

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Sanofi's  executive vice president in charge of strategy and business development, Muzammil Mansuri, a member of the French drugmaker's executive committee, will leave the firm by the end of the month, according to a memo seen by Reuters.

Exclusive: Sanofi's strategy boss to leave as CEO readies revamp

Sanofi's Positive Diabetes Study Offers A New Treatment Alternative For Patients

Sanofi  is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month.

News for Sanofi Stock (SNY)